Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biomed Pharmaceuticals
San Jose, California, USAbiomedind.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biomed Pharmaceuticals has developed a family of patented drugs targeting interconnected neurodegenerative and metabolic diseases. Lead assets are in Phase IIb/III trials for Alzheimer’s disease, ALS, major depressive disorder, diabetes/obesity-related conditions; an infusion system is FDA approved. The company leverages its Unified Acceleration Platform to address systemic drivers of chronic diseases rather than isolated symptoms. No pivotal trial readouts published yet; several programs are late-stage clinical candidates with broad potential applications.
- Therapeutic areas
- PsychiatryNeurologyMetabolic Disorders
- Modalities
- Small moleculePeptidesRecombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on Biomed Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomed Pharmaceuticals.